Circassia Pharmaceuticals : Publication of Circular

27 JUNE 2018

CIRCASSIA PHARMACEUTICALS PLC

PUBLICATION OF CIRCULAR

On 24 April 2018, Circassia Pharmaceuticals plc (the Company) announced that, conditional on the approval of the Company's shareholders, it had agreed to amend certain terms of its development and commercialisation agreement (DCA) with AstraZeneca dated 17 March 2017 and to issue further shares to AstraZeneca in connection therewith (the Transaction).

The Company today announces the publication of a circular (the Circular) containing a notice of general meeting of the Company's shareholders to be convened at 12.00 on 16 July 2018 at the offices of Circassia Pharmaceuticals plc, Northbrook House, Robert Robinson Avenue, The Oxford Science Park, Oxford, Oxfordshire, OX4 4GA, United Kingdom (the General Meeting). At the General Meeting, the Company's independent shareholders will be asked to approve a special resolution to authorise the Transaction as a 'related party transaction' under the Listing Rules. The procedures and timings for shareholders to vote on the special resolution are set out in the notice of the General Meeting in the Circular.

The Circular also includes an update on the Company's free float status and related undertakings to the FCA under the Listing Rules, including the potential move of the Company's listing to AIM. Further background and details regarding this matter are set out on pages 8 and 9 of the Circular.

The Circular and a Form of Proxy in relation to the General Meeting are being posted today, and the Circular will shortly be available for viewing, subject to regulatory requirements, on the Company's website at www.circassia.com/investors/. A copy of the Circular will also be submitted to the National Storage Mechanism and will shortly be available at www.morningstar.co.uk/uk/NSM.

For further information, please contact: